179 related articles for article (PubMed ID: 2498132)
21. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
22. Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging.
Williams IA; Shaw RW
Eur J Obstet Gynecol Reprod Biol; 1990; 34(1-2):111-7. PubMed ID: 2137421
[TBL] [Abstract][Full Text] [Related]
23. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
[TBL] [Abstract][Full Text] [Related]
24. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
[TBL] [Abstract][Full Text] [Related]
25. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
26. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
Nakamura Y; Yoshimura Y
Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
[No Abstract] [Full Text] [Related]
27. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas.
Stovall TG; Ling FW; Henry LC; Woodruff MR
Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1420-3; discussion 1423-5. PubMed ID: 1904681
[TBL] [Abstract][Full Text] [Related]
28. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata.
Palomba S; Affinito P; Tommaselli GA; Nappi C
Fertil Steril; 1998 Jul; 70(1):111-8. PubMed ID: 9660431
[TBL] [Abstract][Full Text] [Related]
29. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
[No Abstract] [Full Text] [Related]
30. Pre-surgical treatment of uterine myomas with LH-RH agonists.
D'Addato F; Repinto A; Andreoli C
Clin Exp Obstet Gynecol; 1992; 19(1):45-50. PubMed ID: 1535032
[TBL] [Abstract][Full Text] [Related]
31. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
[TBL] [Abstract][Full Text] [Related]
32. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
33. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.
Gonzalez-Barcena D; Alvarez RB; Ochoa EP; Cornejo IC; Comaru-Schally AM; Schally AV; Engel J; Reissmann T; Riethmüller-Winzen H
Hum Reprod; 1997 Sep; 12(9):2028-35. PubMed ID: 9363724
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.
Friedman AJ; Barbieri RL; Doubilet PM; Fine C; Schiff I
Fertil Steril; 1988 Mar; 49(3):404-9. PubMed ID: 2963759
[TBL] [Abstract][Full Text] [Related]
35. Major hemorrhage in a patient with multiple submucous leiomyomata during the treatment of long-acting gonadotropin-releasing hormone agonist.
Wang KC; Lee WL; Yuan CC; Wang PH
Kaohsiung J Med Sci; 2000 Feb; 16(2):103-7. PubMed ID: 10816995
[TBL] [Abstract][Full Text] [Related]
36. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.
van Leusden HA; Dogterom AA
Gynecol Endocrinol; 1988 Mar; 2(1):45-51. PubMed ID: 2972173
[TBL] [Abstract][Full Text] [Related]
37. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy.
Broekmans FJ; Hompes PG; Heitbrink MA; Netelenbos CC; Roos JC; Falke TM; Schoemaker J
Am J Obstet Gynecol; 1996 Nov; 175(5):1208-16. PubMed ID: 8942490
[TBL] [Abstract][Full Text] [Related]
38. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
39. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
Flierman PA; Oberyé JJ; van der Hulst VP; de Blok S
BJOG; 2005 May; 112(5):638-42. PubMed ID: 15842290
[TBL] [Abstract][Full Text] [Related]
40. Histopathological changes in leiomyomata treated with leuprolide acetate.
Upadhyaya NB; Doody MC; Googe PB
Fertil Steril; 1990 Nov; 54(5):811-4. PubMed ID: 2121550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
